Mitsumasa Kishimoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mitsumasa Kishimoto has a total of 577 co-authors. Here are the top co-authors by number of shared publications:
Masato Okada
Immuno‐Rheumatology Center, St Luke's International Hospital Tokyo Japan
12 shared publications- Yuko Kaneko
Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
11 shared publications - Shintaro Hirata
Department of Clinical Immunology and Rheumatology Hiroshima University Hospital Hiroshima Japan
10 shared publications - Sho Fukui
Department of Emergency and General Medicine, Kyorin University School of Medicine , Tokyo 181-8611
10 shared publications - Masayoshi Harigai
Department of Rheumatology, International University of Health and Welfare School of Medicine, Chiba, Japan
9 shared publications - Eiichi Tanaka
Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine , Tokyo
8 shared publications
Latest Publications
- 12 November 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (12)
Perspectives of rheumatologists on the management of late-onset rheumatoid arthritis: a nationwide cross-sectional survey
- 12 November 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (12)
Perspectives of rheumatologists on the management of late-onset rheumatoid arthritis: a nationwide cross-sectional survey
- Open Access
- 27 September 2026
- Published by Wiley in Arthritis & Rheumatology
Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA ‐2 Trial
Objective: To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods: In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation of TYK2 Inhibitor (POETYK) PsA‐2 study (NCT04908189), patients were randomized 3:3:1 to deucravacitinib 6 mg daily, placebo, or apremilast 30 mg twice daily (safety reference arm) through week 16 (W16). From W16 to W52, patients continued receiving deucravacitinib or apremilast or switched from placebo to deucravacitinib. The primary endpoint was American College of Rheumatology 20% improvement in response (ACR20) at W16. Secondary endpoints were analyzed per prespecified order to control for multiplicity. Results: Overall, 729 patients were randomized (312 deucravacitinib, 312 placebo, 105 apremilast). Significantly more patients achieved ACR20 at W16 with deucravacitinib versus placebo (54.2% vs 39.4%; P = 0.0002); responses improved beyond W16 and were maintained through W52 (deucravacitinib‐deucravacitinib, 62.2%; placebo‐deucravacitinib, 67.3%). At W16, significant differences in deucravacitinib versus placebo were observed in hierarchical secondary endpoints of Health Assessment Questionnaire Disability Index, 75% improvement in the Psoriasis Area and Severity Index, 36‐Item Short Form Survey Physical Component Summary, and achievement of minimal disease activity. At W16, serious adverse events occurred in 1.0%, 1.9%, and 3.8% of patients receiving placebo, deucravacitinib, and apremilast, respectively. No new safety signals, deaths, or imbalances in cardiovascular events, malignancies, or opportunistic infections occurred through W52. Conclusion: Deucravacitinib was well tolerated in patients with PsA and demonstrated superior efficacy versus placebo across multiple clinical endpoints and patient‐reported outcomes, including functional ability and quality of life. Clinical responses and patient‐reported outcomes were maintained through W52.
- 27 September 2026
- Published by Wiley in Arthritis & Rheumatology
Open AccessDeucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA ‐2 Trial
Objective: To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods: In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation of TYK2 Inhibitor (POETYK) PsA‐2 study (NCT04908189), patients were randomized 3:3:1 to deucravacitinib 6 mg daily, placebo, or apremilast 30 mg twice daily (safety reference arm) through week 16 (W16). From W16 to W52, patients continued receiving deucravacitinib or apremilast or switched from placebo to deucravacitinib. The primary endpoint was American College of Rheumatology 20% improvement in response (ACR20) at W16. Secondary endpoints were analyzed per prespecified order to control for multiplicity. Results: Overall, 729 patients were randomized (312 deucravacitinib, 312 placebo, 105 apremilast). Significantly more patients achieved ACR20 at W16 with deucravacitinib versus placebo (54.2% vs 39.4%; P = 0.0002); responses improved beyond W16 and were maintained through W52 (deucravacitinib‐deucravacitinib, 62.2%; placebo‐deucravacitinib, 67.3%). At W16, significant differences in deucravacitinib versus placebo were observed in hierarchical secondary endpoints of Health Assessment Questionnaire Disability Index, 75% improvement in the Psoriasis Area and Severity Index, 36‐Item Short Form Survey Physical Component Summary, and achievement of minimal disease activity. At W16, serious adverse events occurred in 1.0%, 1.9%, and 3.8% of patients receiving placebo, deucravacitinib, and apremilast, respectively. No new safety signals, deaths, or imbalances in cardiovascular events, malignancies, or opportunistic infections occurred through W52. Conclusion: Deucravacitinib was well tolerated in patients with PsA and demonstrated superior efficacy versus placebo across multiple clinical endpoints and patient‐reported outcomes, including functional ability and quality of life. Clinical responses and patient‐reported outcomes were maintained through W52.
- Open Access
- 1 July 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (7)
Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: novel insights from FOREMOST
Objectives: Data regarding progression from oligoarticular to polyarticular psoriatic arthritis (PsA) are sparse. Using FOREMOST, we identify progression predictors and evaluate apremilast’s treatment effect in early PsA. Methods: FOREMOST (NCT03747939) randomised N = 308 patients with early (mean duration, 9.9 months) PsA and limited joint involvement (>1 to ≤ 4 swollen and >1 to ≤ 4 tender joints; not confirmed by imaging) to apremilast or placebo for 24 weeks, followed by open-label apremilast through week 48. Multivariable logistic regression modelled predictors of progression from oligoarticular (≤4 active [swollen and/or tender] joints) to polyarticular (>4 active joints) PsA at week 16 and the effect of apremilast. Disease progression, disease activity, clinical signs/symptoms, and tolerability were summarized through week 48 for N = 291 patients receiving ≥1 apremilast dose (from randomization or switched from placebo). Results: Most (268/308 [87.0%]) patients had oligoarticular PsA at baseline; 25.1% (59/235) progressed to polyarticular PsA by week 16 (data as observed). Apremilast reduced odds of progression vs placebo by 58% (Odds Ratio [OR; 95% CI]: 0.42 [0.22, 0.77]). In placebo-treated patients, being female, being csDMARD-naïve, and having dactylitis significantly increased odds of progression (OR: 3.35 [1.20, 9.34], 3.42 [1.18, 9.93], and 9.26 [1.32, 65.09], respectively). Apremilast treatment for up to 48 weeks maintained low rates of disease progression and improvements in disease activity/clinical signs and symptoms, with no new safety signals. Conclusion: Initiating apremilast treatment during the early, oligoarticular phase of PsA reduced disease activity and delayed progression to polyarticular disease, with benefits maintained with up to 48 weeks of treatment. Trial Registration: ClinicalTrials.gov; NCT03747939
- 1 July 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (7)
Open AccessProgression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: novel insights from FOREMOST
Objectives: Data regarding progression from oligoarticular to polyarticular psoriatic arthritis (PsA) are sparse. Using FOREMOST, we identify progression predictors and evaluate apremilast’s treatment effect in early PsA. Methods: FOREMOST (NCT03747939) randomised N = 308 patients with early (mean duration, 9.9 months) PsA and limited joint involvement (>1 to ≤ 4 swollen and >1 to ≤ 4 tender joints; not confirmed by imaging) to apremilast or placebo for 24 weeks, followed by open-label apremilast through week 48. Multivariable logistic regression modelled predictors of progression from oligoarticular (≤4 active [swollen and/or tender] joints) to polyarticular (>4 active joints) PsA at week 16 and the effect of apremilast. Disease progression, disease activity, clinical signs/symptoms, and tolerability were summarized through week 48 for N = 291 patients receiving ≥1 apremilast dose (from randomization or switched from placebo). Results: Most (268/308 [87.0%]) patients had oligoarticular PsA at baseline; 25.1% (59/235) progressed to polyarticular PsA by week 16 (data as observed). Apremilast reduced odds of progression vs placebo by 58% (Odds Ratio [OR; 95% CI]: 0.42 [0.22, 0.77]). In placebo-treated patients, being female, being csDMARD-naïve, and having dactylitis significantly increased odds of progression (OR: 3.35 [1.20, 9.34], 3.42 [1.18, 9.93], and 9.26 [1.32, 65.09], respectively). Apremilast treatment for up to 48 weeks maintained low rates of disease progression and improvements in disease activity/clinical signs and symptoms, with no new safety signals. Conclusion: Initiating apremilast treatment during the early, oligoarticular phase of PsA reduced disease activity and delayed progression to polyarticular disease, with benefits maintained with up to 48 weeks of treatment. Trial Registration: ClinicalTrials.gov; NCT03747939
- 1 April 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (10) , 2033-2043
Peripheral blood UBA1 variant burden predicts poor outcomes in VEXAS syndrome: a nationwide prospective study
- 1 April 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (10) , 2033-2043
Peripheral blood UBA1 variant burden predicts poor outcomes in VEXAS syndrome: a nationwide prospective study
- 25 January 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (3) , 724-733
Longitudinal Changes in Serum Urate Levels From Premenopause Through Postmenopause: Interrupted Time‐Series Analyses
Objective: Hyperuricemia (HU) and gout are common in postmenopausal women. We aimed to identify the longitudinal changes in serum urate (SU) levels during and after the menopausal transition and its interaction with coexisting SU‐modifying conditions. Methods: This longitudinal study included Japanese women who underwent annual medical examinations from April 2004 to September 2024 and had at least one visit before and after self‐reported menopause. Menopausal transition stages were categorized into premenopause, perimenopause (5 years before and up to the menopause), and postmenopause. Longitudinal changes in SU and HU (SU ≥6.8 mg/dL or taking medications for gout or HU) were examined by interrupted time‐series analyses and evaluated across stratified subgroups. Results: We analyzed 8,169 eligible participants with 93,511 visits over a median follow‐up of 13.8 years. SU levels gradually increased during premenopause, rose sharply over perimenopause, and stabilized in postmenopause. Compared to premenopause, the mean SU level was 0.41 mg/dL (95% confidence interval: 0.38–0.43) higher in postmenopause. HU prevalence increased from 2 ) and a high body mass index (≥25) with HU were greater in postmenopause; HU was observed in approximately 18% of overweight or obese women at menopause. Conclusion: SU levels rapidly increase during perimenopause and are already elevated by the time of menopause. Maintaining a normal body weight and preserving kidney function before menopause may decrease postmenopausal HU and potentially prevent subsequent gout in women. image
- 25 January 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (3) , 724-733
Longitudinal Changes in Serum Urate Levels From Premenopause Through Postmenopause: Interrupted Time‐Series Analyses
Objective: Hyperuricemia (HU) and gout are common in postmenopausal women. We aimed to identify the longitudinal changes in serum urate (SU) levels during and after the menopausal transition and its interaction with coexisting SU‐modifying conditions. Methods: This longitudinal study included Japanese women who underwent annual medical examinations from April 2004 to September 2024 and had at least one visit before and after self‐reported menopause. Menopausal transition stages were categorized into premenopause, perimenopause (5 years before and up to the menopause), and postmenopause. Longitudinal changes in SU and HU (SU ≥6.8 mg/dL or taking medications for gout or HU) were examined by interrupted time‐series analyses and evaluated across stratified subgroups. Results: We analyzed 8,169 eligible participants with 93,511 visits over a median follow‐up of 13.8 years. SU levels gradually increased during premenopause, rose sharply over perimenopause, and stabilized in postmenopause. Compared to premenopause, the mean SU level was 0.41 mg/dL (95% confidence interval: 0.38–0.43) higher in postmenopause. HU prevalence increased from 2 ) and a high body mass index (≥25) with HU were greater in postmenopause; HU was observed in approximately 18% of overweight or obese women at menopause. Conclusion: SU levels rapidly increase during perimenopause and are already elevated by the time of menopause. Maintaining a normal body weight and preserving kidney function before menopause may decrease postmenopausal HU and potentially prevent subsequent gout in women. image
- Open Access
- 3 November 2025
- Published by Springer Nature in BMC Rheumatology
- Vol. 9 (1) , 1-10
Disease phenotype and management of axial psoriatic arthritis in Japan compared with other regions, particularly other Asian countries: results of the ASAS-PerSpA study
This study evaluated the disease phenotype and treatment of axial psoriatic arthritis among patients from Japan compared with those from different geographic regions. Data from the ASAS-PerSpA study were analyzed. Patients with psoriatic arthritis (PsA) with axial involvement, according to a rheumatologist´s judgment, were included. Patients were further categorized by four geographic regions: Europe/North America, Latin America, Middle East/North Africa, and Asia, split into Japan and other Asian countries. Disease and patient characteristics, disease activity, function, and treatment were compared by region. Of the 4,465 patients with SpA, 1,033 (23%) were diagnosed with PsA by their rheumatologist. Among those with PsA, 367 (35.5%) had axial involvement (axPsA). Disease activity and function ranges were 4.1–5.4 for BASDAI, 2.5–3.2 for ASDAS, and 3.0–4.7 for BASFI, by regions. In Japan, disease activity and function were relatively lower, indicated by a mean BASDAI of 3.5 (SD 2.4), ASDAS of 2.2 (SD 1.0), and BASFI of 1.6 (SD 2.3). These indexes were also significantly lower than those in other Asian countries, with scores of 4.8 (SD 3.0), 2.2 (SD 2.4), and 3.2 (SD 1.5) respectively. All regions showed variations in the use of csDMARDs and bDMARDs, the utilization rate of csDMARDs was significantly lower in Japan than in other Asian countries (51.4% vs. 78.1%, p = 0.02). Patients with axPsA in Japan showed relatively lower disease activity and function than those from different geographic regions, especially in other Asian countries with less frequent csDMARD use.
- 3 November 2025
- Published by Springer Nature in BMC Rheumatology
- Vol. 9 (1) , 1-10
Open AccessDisease phenotype and management of axial psoriatic arthritis in Japan compared with other regions, particularly other Asian countries: results of the ASAS-PerSpA study
This study evaluated the disease phenotype and treatment of axial psoriatic arthritis among patients from Japan compared with those from different geographic regions. Data from the ASAS-PerSpA study were analyzed. Patients with psoriatic arthritis (PsA) with axial involvement, according to a rheumatologist´s judgment, were included. Patients were further categorized by four geographic regions: Europe/North America, Latin America, Middle East/North Africa, and Asia, split into Japan and other Asian countries. Disease and patient characteristics, disease activity, function, and treatment were compared by region. Of the 4,465 patients with SpA, 1,033 (23%) were diagnosed with PsA by their rheumatologist. Among those with PsA, 367 (35.5%) had axial involvement (axPsA). Disease activity and function ranges were 4.1–5.4 for BASDAI, 2.5–3.2 for ASDAS, and 3.0–4.7 for BASFI, by regions. In Japan, disease activity and function were relatively lower, indicated by a mean BASDAI of 3.5 (SD 2.4), ASDAS of 2.2 (SD 1.0), and BASFI of 1.6 (SD 2.3). These indexes were also significantly lower than those in other Asian countries, with scores of 4.8 (SD 3.0), 2.2 (SD 2.4), and 3.2 (SD 1.5) respectively. All regions showed variations in the use of csDMARDs and bDMARDs, the utilization rate of csDMARDs was significantly lower in Japan than in other Asian countries (51.4% vs. 78.1%, p = 0.02). Patients with axPsA in Japan showed relatively lower disease activity and function than those from different geographic regions, especially in other Asian countries with less frequent csDMARD use.
- Open Access
- 9 October 2025
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 36 (2) , 307-312
High glucocorticoid dependency and limited therapeutic response in Japanese patients with VEXAS syndrome: a multicentre retrospective study
Objectives: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is an autoinflammatory disease caused by somatic variants of the UBA1 gene. Due to uncertainty around treatment strategies and limited therapeutic options, this study aimed to characterise the clinical treatment and outcomes of VEXAS syndrome patients in Japan. Methods: We retrospectively analysed data on clinical manifestations, treatments, and outcomes from 46 male patients diagnosed with VEXAS syndrome. Twelve patients at our institution were evaluated for remission using the French VEXAS group criteria. Results: All patients (median age at onset: 71.4 years) received systemic glucocorticoid therapy (mean maximum dose: 47.4 mg/day; mean minimum dose: 8.5 mg/day). Most patients required continuous glucocorticoid treatment of ≥10 mg/day, and tapering was generally difficult. Among the patients followed at our institution, only 42% (5/12) achieved complete remission at least once during follow-up. Tocilizumab was the most frequently administered immunosuppressant (n = 24, 52.2%); Janus kinase inhibitors and azacitidine, reported to be effective overseas, were prescribed in only three and two cases, respectively. Conclusions: This study highlights the difficulty of treating patients with VEXAS syndrome in Japan. The development of more effective treatments is urgently needed to reduce glucocorticoid dependence and improve patient outcomes.
- 9 October 2025
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 36 (2) , 307-312
Open AccessHigh glucocorticoid dependency and limited therapeutic response in Japanese patients with VEXAS syndrome: a multicentre retrospective study
Objectives: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is an autoinflammatory disease caused by somatic variants of the UBA1 gene. Due to uncertainty around treatment strategies and limited therapeutic options, this study aimed to characterise the clinical treatment and outcomes of VEXAS syndrome patients in Japan. Methods: We retrospectively analysed data on clinical manifestations, treatments, and outcomes from 46 male patients diagnosed with VEXAS syndrome. Twelve patients at our institution were evaluated for remission using the French VEXAS group criteria. Results: All patients (median age at onset: 71.4 years) received systemic glucocorticoid therapy (mean maximum dose: 47.4 mg/day; mean minimum dose: 8.5 mg/day). Most patients required continuous glucocorticoid treatment of ≥10 mg/day, and tapering was generally difficult. Among the patients followed at our institution, only 42% (5/12) achieved complete remission at least once during follow-up. Tocilizumab was the most frequently administered immunosuppressant (n = 24, 52.2%); Janus kinase inhibitors and azacitidine, reported to be effective overseas, were prescribed in only three and two cases, respectively. Conclusions: This study highlights the difficulty of treating patients with VEXAS syndrome in Japan. The development of more effective treatments is urgently needed to reduce glucocorticoid dependence and improve patient outcomes.
- 27 September 2025
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 39 (4) , 102103
Novel Therapy
- 27 September 2025
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 39 (4) , 102103
Novel Therapy
- 18 September 2025
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 61 (1) , 46-58
Prevalence, characteristics, and screening of spondyloarthritis in Japanese patients with early inflammatory bowel diseases: a prospective multidisciplinary study
Background The prevalence and characteristics of inflammatory bowel disease-associated spondyloarthritis (IBD-SpA) in Japan are unclear. Moreover, methods for screening SpA among IBD patients have not been established. Methods This single-center prospective multidisciplinary study included consecutive patients with IBD, which was newly diagnosed within the past 3 years (early IBD). Board-certified rheumatologists examined the patients for disease history and musculoskeletal manifestations, with imaging studies if needed. Questionnaires assessed patient-reported outcomes and Psoriatic Arthritis Screening and Evaluation (PASE) scores. Results We identified 85 eligible patients with early IBD, 22 (25.9%) of whom had Crohn’s disease, 63 (74.1%) had ulcerative colitis, and 3 (3.5%) had IBD-SpA diagnosed prior to study enrollment. Rheumatologist evaluations identified additional seven SpA cases, resulting in a total of 10 patients (11.8%) with IBD-SpA (1: axial, 9: peripheral). IBD patients without SpA often presented with back pain (52%) and peripheral joint pain (24%), whereas arthritis, cervical and thoracic pain, and inflammatory back pain were more frequent in IBD-SpA. Newly identified IBD-SpA cases tended to have lower-limb arthritis, dactylitis, and enthesitis, compared with previously diagnosed IBD-SpA cases. For patients with active SpA symptoms in the past 6 months, PASE demonstrated that the area under the receiver operating characteristic curve was 0.87 (95% confidence interval: 0.68, 1.00). The optimal cut-off (33 points) had a sensitivity of 0.88 and specificity of 0.88. Conclusions This prospective study found rheumatologist evaluation increased SpA diagnosis and 11.8% of Japanese early IBD patients had IBD-SpA. PASE questionnaires may be effective for screening SpA among IBD patients.
- 18 September 2025
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 61 (1) , 46-58
Prevalence, characteristics, and screening of spondyloarthritis in Japanese patients with early inflammatory bowel diseases: a prospective multidisciplinary study
Background The prevalence and characteristics of inflammatory bowel disease-associated spondyloarthritis (IBD-SpA) in Japan are unclear. Moreover, methods for screening SpA among IBD patients have not been established. Methods This single-center prospective multidisciplinary study included consecutive patients with IBD, which was newly diagnosed within the past 3 years (early IBD). Board-certified rheumatologists examined the patients for disease history and musculoskeletal manifestations, with imaging studies if needed. Questionnaires assessed patient-reported outcomes and Psoriatic Arthritis Screening and Evaluation (PASE) scores. Results We identified 85 eligible patients with early IBD, 22 (25.9%) of whom had Crohn’s disease, 63 (74.1%) had ulcerative colitis, and 3 (3.5%) had IBD-SpA diagnosed prior to study enrollment. Rheumatologist evaluations identified additional seven SpA cases, resulting in a total of 10 patients (11.8%) with IBD-SpA (1: axial, 9: peripheral). IBD patients without SpA often presented with back pain (52%) and peripheral joint pain (24%), whereas arthritis, cervical and thoracic pain, and inflammatory back pain were more frequent in IBD-SpA. Newly identified IBD-SpA cases tended to have lower-limb arthritis, dactylitis, and enthesitis, compared with previously diagnosed IBD-SpA cases. For patients with active SpA symptoms in the past 6 months, PASE demonstrated that the area under the receiver operating characteristic curve was 0.87 (95% confidence interval: 0.68, 1.00). The optimal cut-off (33 points) had a sensitivity of 0.88 and specificity of 0.88. Conclusions This prospective study found rheumatologist evaluation increased SpA diagnosis and 11.8% of Japanese early IBD patients had IBD-SpA. PASE questionnaires may be effective for screening SpA among IBD patients.